These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15847658)

  • 1. Oxaliplatin-induced immune pancytopenia.
    Taleghani BM; Meyer O; Fontana S; Ahrens N; Novak U; Borner MM; Salama A
    Transfusion; 2005 May; 45(5):704-8. PubMed ID: 15847658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated pancytopenia induced by oxaliplatin: a case report.
    Fontão-Wendel R; Hoff PM; Lazar A; Freitas D; Novis Y; Patah P; Tsujita M; Balthazar A; Pierroti M; Wendel S
    Transfusion; 2010 Jul; 50(7):1453-9. PubMed ID: 20210930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
    James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
    Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-induced immune mediated thrombocytopenia.
    Beg MS; Komrokji RS; Ahmed K; Safa MM
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
    Cobo F; De Celis G; Pereira A; Latorre X; Pujadas J; Albiol S
    Anticancer Drugs; 2007 Sep; 18(8):973-6. PubMed ID: 17667605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug-induced nonimmunologic protein adsorption.
    Arndt P; Garratty G; Isaak E; Bolger M; Lu Q
    Transfusion; 2009 Apr; 49(4):711-8. PubMed ID: 19192254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.
    Dahabreh I; Tsoutsos G; Tseligas D; Janinis D
    BMC Clin Pharmacol; 2006 Sep; 6():5. PubMed ID: 16968538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis.
    Koutras AK; Makatsoris T; Paliogianni F; Kopsida G; Onyenadum A; Gogos CA; Mouzaki A; Kalofonos HP
    Oncology; 2004; 67(2):179-82. PubMed ID: 15539924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells.
    Grossjohann B; Eichler P; Greinacher A; Santoso S; Kroll H
    Transfusion; 2004 Jul; 44(7):1033-40. PubMed ID: 15225244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
    Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
    J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia.
    Curtis SA; Curtis BR; Lee AI; Hendrickson JE; Lacy J; Podoltsev NA
    Hematology; 2018 Aug; 23(7):429-432. PubMed ID: 29281948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
    Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
    Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
    Chen VM; Thrift KM; Morel-Kopp MC; Jackson D; Ward CM; Flower RL
    Transfusion; 2004 Jun; 44(6):838-43. PubMed ID: 15157248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersensitivity reactions to oxaliplatin in two asian patients.
    Ng CV
    Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin hypersensitivity: case report and successful repeat desensitization.
    Edmondson DA; Gruling BJ; Urmanski AM; Wong SJ; Levy MB
    Am J Ther; 2007; 14(1):116-8. PubMed ID: 17303980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
    Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
    Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
    Wenzel C; Urbauer E; Schwarz C; Funk G; Oehler L; Kornek GV; Scheithauer W
    Anticancer Drugs; 2006 Aug; 17(7):865-8. PubMed ID: 16926637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.